Clinical Trials Logo
  1. Home
  2. Dermatology/Skin - Other
  3. NCT03893643

Cutaneous and Mucosal Manifestations of Neurofribromatosis Type 2 in Children Under 15

Neurofibromatosis 2 Clinical Trial

Official title:
Multicentre Prospective Observational Study: Resentment of Mucocutaneous Manifestations and the Value of Dermatological Examination in the Early Detection of Type 2 Neurofibromatosis in Children Under 15 Years of Age

Clinical Trial Summary

.Neurofibromatosis type 2 is an inherently autosomal dominant genetic disease, but cases of mosaicism or de novo mutation are not uncommon. the prevalence is estimated at 1 / 60,000. the clinical presentation is based on the appearance of tumors in the central and peripheral nervous system. The current average age of diagnosis is around 25 to 30 years depending on the studies. Currently, the diagnostic criteria are based on the ENT, neurological and opthalmological manifestations of the disease. Cutaneous manifestations have been described in these patients. Except now, mucocutaneous manifestations of the disease are not taken into account for depisatage or diagnosis.

The purpose of this study would be to identify the different cutaneous and mucosal manifestations in a pediatric population under 15 years of age, and to analyze whether this might be of interest in early detection of the disease in association with other symptoms.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03893643
Study type Observational
Source Centre Hospitalier Universitaire de Nice
Contact Sophie LEGOUPIL
Phone 336 81818020
Email sophie.legoupil@hotmail.fr
Status Recruiting
Phase
Start date January 1, 2019
Completion date December 31, 2022
View Details
See also
  Status Clinical Trial Phase
Completed NCT03617276 - Reliability of Functional Outcome Measures in Neurofibromatosis 2
Active, not recruiting NCT00973739 - Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Phase 2
Completed NCT00030043 - An Implant for Hearing Loss Due to Removal of Neurofibromatosis 2 Tumors Phase 1
Recruiting NCT05685836 - 89Zr-Bevacizumab PET/CT Imaging in NF2 Patients
Completed NCT00004437 - Phase II Study of the Multichannel Auditory Brain Stem Implant for Deafness Following Surgery for Neurofibromatosis 2 Phase 2
Recruiting NCT03406208 - Resiliency Training for Adults With Neurofibromatosis Via Live Videoconferencing N/A
Active, not recruiting NCT03095248 - Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors Phase 2
Completed NCT02298270 - Resiliency Training for Patients With Neurofibromatosis Via Videoconferencing With Skype N/A
Recruiting NCT01885767 - Neurofibromatosis (NF) Registry Portal
Completed NCT00863122 - Concentration and Activity of Lapatinib in Vestibular Schwannomas Early Phase 1
Recruiting NCT03079999 - Study of Aspirin in Patients With Vestibular Schwannoma Phase 2
Terminated NCT00911248 - PTC299 for Treatment of Neurofibromatosis Type 2 Phase 2
Completed NCT02811718 - Resiliency Training for Patients With NF2 Via Videoconferencing With Skype N/A
Enrolling by invitation NCT04890132 - Vestibular Precision: Physiology & Pathophysiology N/A
Completed NCT01490476 - Efficacy and Safety Study of RAD001 in the Growth of the Vestibular Schwannoma(s) in Neurofibromatosis 2 (NF2) Patients Phase 2
Active, not recruiting NCT00004483 - NF2 Natural History Consortium N/A
Active, not recruiting NCT04283669 - Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas Phase 2
Completed NCT02831257 - AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas Phase 2